Synchron

The company's flagship product involves a minimally invasive endovascular procedure, akin to the placement of stents, which eliminates the need for open brain surgery. This procedure allows the BCI to be implanted safely and efficiently, making it accessible to a broader range of patients.

Synchron primarily serves patients with neurological conditions that impair their ability to communicate or move. These clients benefit from the ability to control computers and other digital devices using their thoughts, significantly improving their quality of life. The company operates in the medical technology market, which is rapidly growing due to advancements in healthcare and increasing demand for innovative treatments.

The business model of Synchron revolves around the development, clinical testing, and commercialization of its BCI technology. The company generates revenue through the sale of its medical devices and related services. Additionally, Synchron may engage in partnerships with healthcare providers and institutions to expand the reach and application of its technology.

The leadership team at Synchron comprises global experts in neuroscience, vascular bionics, and medical technology, including CEO Tom Oxley and Founding Director Nick Opie. Their combined expertise drives the company's mission to empower patients and transform medicine.

In summary, Synchron is at the forefront of medical innovation, offering groundbreaking solutions for patients with severe neurological impairments. By leveraging advanced BCI technology, the company is making significant strides in improving patient autonomy and social connectivity.